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Introduction 
Myocardial stunning and ischemia might occur 
during cardiac surgery to variable degrees with 
subsequent myocardial dysfunction. Different 
methods have been used to reduce myocardial 
damage during cardiac surgery [1]. Severe 
myocardial dysfunction can be managed 
pharmacologically with catecholamines, 
phosphodiesterase III inhibitors, and calcium-
sensitizer (levosimendan), or mechanically with 
an intra-aortic balloon pump (IABP) or both [2].  
Catecholamines are β-1 adrenergic agonists, 
which increases the cyclic adenosine 
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Abstract 
Background: Levosimendan is a calcium sensitizer with positive inotropic, 
vasodilatory, and cardioprotective actions. Levosimendan infusion time may affect 
the outcomes. Our objective was to evaluate its efficacy and safety when used 
before coronary artery bypass grafting (CABG) in patients with low ejection fraction. 
Methods: This prospective observational study included 150 CABG patients with 
ejection fraction ≤ 40% divided into two groups. In the Levosimendan group (n= 75), 
it was given preoperatively, and in the conventional group (n= 75), myocardial 
support was used if indicated.  
Results: Operative time (344±28.7 vs. 421.4±34.5 min) and cardiopulmonary bypass 
time (97±17.4 vs. 127.4±24.5) were significantly shorter in the Levosimendan group 
(P˂ 0.001, for both). Failure to wean from bypass (13 (17.3%) vs. 23 (30.7%), P=0.06) 
and the need for intra-aortic balloon pump (6 (8%) vs. 14 (18.7%), P= 0.06) were non 
significantly lower in the Levosimendan group. The mechanical ventilation duration 
(12±3.3 vs. 19.6±4.7 h, P= 0.04) and ICU stay (3.8±1.2 vs. 5.3±1.4 days, P ˂ 0.001) 
were lower with levosimendan. Mortality was non-significantly lower in the 
Levosimendan group (10 (13.3%) vs. 18 (24%), P= 0.09). There were no differences 
in atrial and ventricular arrhythmias between groups.  
Conclusion: The preoperative use of levosimendan could improve the outcomes in 
patients undergoing CABG with low ejection fraction. Levosimendan complication 









monophosphate (cAMP). Phosphodiesterase 
inhibitors, such as milrinone, inhibit cAMP 
degradation and elevate intracellular myocardial 
calcium levels. On the other hand, levosimendan 
is a calcium-sensitizing agent that binds to 
troponin C and makes the myocardial cells more 
responsive to calcium. This action has an 
inotropic effect on the cardiac muscle [3].  
Moreover, the levosimendan's active 
metabolites remain in circulation for about one 
week [4]. Therefore, the levosimendan 
administration preoperatively could provide more 
benefits over intraoperative or postoperative use. 
The preoperative administration allows for the 
accumulation of levosimendan's metabolites with 
better hemodynamic support during surgery [5]. 
However, preoperative use may increase the 
adverse effects, such as arrhythmia, hypotension, 
headache, and renal impairment [6]. We aimed 
to study the efficacy and safety of preoperative 
use of levosimendan in patients undergoing 
coronary artery bypass grafting (CABG) with low 
ejection fraction (EF). 
Patients and methods: 
Research design: 
This study is a prospective observational study 
that included 150 CABG patients with low EF (≤ 
40%). This study was conducted in the 
cardiothoracic surgery department at Benha 
University Hospital from March 2017 to October 
2020. We allocated patients into two groups. 
Group A (levosimendan group, n= 75) included 
patients admitted to the intensive care unit (ICU) 
24 hours before surgery and received 
levosimendan by continuous infusion at a dose of 
0.1 μg/kg/min. Group B (conventional group, n= 
75) included patients who received levosimendan
intraoperative or postoperative when needed. 
Inclusion and exclusion criteria: 
We included patients with isolated on-pump 
CABG with no concomitant valve lesions and 
preoperative EF ≤ 40%. We excluded patients 
older than 75 or younger than 20 years, patients 
with chronic chest, liver, or kidney diseases, redo 
CABG, and patients undergoing other concomitant 
cardiac surgeries. 
Outcomes: 
All patients had a thorough preoperative 
evaluation. Preoperative, intraoperative, and 
postoperative data, such as the duration of 
mechanical ventilation, use of inotropes and IABP, 
ICU and hospital stay, and mortality, were 
collected. Our primary outcome was the 30-day 
mortality. The secondary outcomes included 
intraoperative and postoperative low cardiac 
output, duration of mechanical ventilation, ICU, 
and hospital stay. 
Statistical analysis 
All statistical calculations were done using 
SPSS statistical program version 23 (IBM Corp, 
Armonk, NY, USA). Data were described using 
mean, standard deviation (SD), frequencies, and 
percentages. A comparison of quantitative 
variables was done using the Mann-Whitney U 
test and Chi-square (×²) or Fisher exact test for 
qualitative variables. A probability value (Ρ-value) 




There was no significant statistical difference 
between both groups regarding age, sex, body 
mass index (BMI), preoperative EF, heart rate and 
blood pressure, and New York Heart Association 
(NYHA) dyspnea class. (Table 1) 
Operative data:  
There was a significant difference between 
both groups regarding total operative and bypass 
times. Failure of weaning from cardiopulmonary 
bypass (CPB) and IABP use were non-significantly 
higher in Group B. There was no significant 
statistical difference regarding the cross-clamp 
time and the number of grafts used (p= 0.45 and 
0.99, respectively). (Table 2). 
Postoperative data: 
There was no statistical difference in 
arrhythmia between groups. Hypotension was 
more frequent in the levosimendan group but 
without significant difference. The need for 
Inotropic support was significantly higher in Group 
B (p= 0.02). However, the rate of ICU-IABP use was 
not significantly different between groups. There




Table 1: Comparison between the two groups' demographics and clinical parameters. Data were presented as mean 
and SD or number (%) 
Group A (n=75) Group B (n=75) P-value 
Age (years) 57.3±10.5 58.4±11.2 0.75 
Male 48(64%) 51(68%) 0.39 
BMI (kg/m2) 30.8 ± 5.7 32.3 ± 3.1 0.67 
Medical history 
Smoking 41 (54.7%) 45 (60%) 0.26 
Diabetes Mellitus 57 (76%) 54 (72%) 0.39 
Hypertension 64 (85.3%) 66 (88%) 0.57 
Atrial Fibrillation 12 (16%) 9 (12%) 0.4 
Heart rate (b/min) 83.6±9.3 84.7±8.3 0.75 
Diastolic BP (mmHg) 76.3±12 81.2±13.7 0.17 
Systolic BP (mmHg) 122.8±18.7 128.4±20.6 0.12 
Ejection fraction (%) 36.5±3.1 35.7± 4.3 0.82 
NYHA class 
II 29 (38.7%) 33(44%) 
0.26 III 40(53.3%) 36(48%) 
IV 6(8%) 6(8%) 
BMI: body mass index; BP: blood pressure; NYHA: New York Heart Association 
was a significant difference in ventilation and 
ICU stay between groups. (Table 3) 
Discussion 
Coronary artery bypass grafting in patients 
with low EF is challenging. Therefore, we 
evaluated if preoperative levosimendan could 
improve the outcomes in those patients. Previous 
studies showed that levosimendan's benefit was 
confined to the low EF patients [7, 8]. Starting the 
treatment with levosimendan before myocardial 
ischemia will cause a similar effect to ischemic 
preconditioning [9]. An expert statement 
recommended the preoperative use of 
levosimendan one day before surgery in patients 
with low myocardial function, including right 
ventricular dysfunction [9]. Preoperative infusion 
resulted in significant and persistent 
hemodynamic optimization and increased the 
tolerance to surgical injury [2,7]. A systematic 
review revealed that levosimendan's benefits 
were more pronounced when used preoperative 
[10].
Table 2: Comparison between the two groups regarding operative data. Data were presented as mean and SD or 
number (%) 
Group A (n=75) Group B (n=75) P-value 
Operative time (min) 344±28.7 421.4±34.5 ˂ 0.001 
CPB time (min) 97±17.4 127.4±24.5 ˂ 0.001 
Cross-clamp time (min) 69.1±13.6 66.4±11.4 0.45 
Number of grafts 3± 1 3± 1 >0.99 
CPB weaning failure 
First weaning failure 13 (17.3%) 23 (30.7%) 0.06 
Second weaning failure 6 (8%) 14 (18.7%) 0.06 
Intraoperative IABP 6 (8%) 14 (18.7%) 0.06 






Table 3: Comparison between the two groups regarding postoperative data. Data were presented as mean and SD or 
number (%) 
Group A (n=75) Group B (n=75) P-value 
Tachyarrhythmia post-bypass 
Atrial fibrillation 20 (26.7%) 18 (24%) 0.57 
Ventricular tachycardia or fibrillation 12 (16%) 15 (20%) 0.4 
Hypotension  28 (37.3%) 23 (30.7%) 0.17 
Use of inotropes 37 (49.3%) 52 (69.3%) ˂ 0.001 
IABP (postoperative) 5 (6.7%) 8 (10.7%) 0.4 
Mechanical ventilation (h) 12±3.3 19.6±4.7 0.04 
ICU stay (days) 3.8±1.2 5.3±1.4 ˂ 0.001 
Hospital stay (days) 9.4±1.6 10.6±2.7 0.73 
Pre-discharge EF (%) 55.4±5.2 53.8±6.5 0.65 
Mortality 10 (13.3%) 18 (24%) 0.09 
EF: ejection fraction, IABP: intra-aortic balloon pump; ICU: intensive care unit 
On the other hand, intraoperative use of 
levosimendan led to a reduction in the rate for 
reintubation, ICU and hospital stay time, a lower 
incidence of sepsis, and a lower mortality rate 
compared to the postoperative use [1,11].  
The recommended dose of levosimendan is 
0.1 μg/kg/min infusion for 24 h with a starting 
bolus dose of 12 μg/kg in 10 min Infusion. Toller 
and associates advised against the bolus dose 
when used preoperatively, as there is enough 
time to get the drug's best plasma level [9]. 
However, when used intraoperatively, patients 
who received the bolus dose followed by infusion 
had a lower mortality rate [10].  
In our study, although the recorded 
hypotension was not significant between both 
groups, the need for inotropic support was 
significantly more frequent in the conventional 
group. This finding was explained by considering 
that the hypotension was caused by 
levosimendan's vasodilatation effect and not a 
form of LCOS.  In seven studies, the levosimendan 
group had significantly less evidence of LCOS than 
the placebo group [10]. A placebo-controlled 
study involving 106 patients reported lower 
inotropic requirements with the levosimendan 
group [1]. Additionally, these patients 
experienced significantly fewer LCOS events and 
needed less inotropic support after a day of 
infusion [6]. Furthermore, Levin and colleagues 
found that fewer patients required the addition of 
inotropic agents and vasopressors in the 
levosimendan group versus the control group [7].  
There was a difference between both groups 
regarding the rate of intra-aortic balloon use. After 
the first weaning attempt's failure, epinephrine 
was added with resuming bypass and revising 
blood gases, electrolytes, and temperature. After 
the failure of the second time, the IABP was 
inserted. However, this rate was not significant in 
the ICU as we have decided to insert the IAB as 
early as possible. Others have demonstrated the 
same finding as reported by Levin and coworkers 
that (6.3%) patients treated with levosimendan 
received an IABP compared to (30.4%) in the 
control group [7]. Moreover, Severi and 
associates have supported the benefits of 
levosimendan over the IABP. Many patients with 
contraindications to the IABP had the best 
benefit from levosimendan [12].   
The ventilation time was significantly 
prolonged in the conventional group. This finding 
was expected because of the higher rate of IABP 
use, the more frequent LCOS, and the more need 
for inotropes in this group. Similar data were 
reported in a study involving 106 patients where 
the levosimendan group showed lower myocardial 
injury and decreased time on the ventilator [1]. 
Furthermore, in a meta-analysis, four studies that 
included 165 patients with low preoperative EF 
showed a significantly shorter ventilation duration 





in the Levosimendan group than the placebo 
group [10].  
In the present study, the duration of ICU and 
hospital stay were shorter with levosimendan. 
This was explained by the early mortality cases, 
which were eliminated during the calculation of 
the length of stay. A meta-analysis of eight studies 
investigated the length of ICU stay, and patients 
who received levosimendan showed significantly 
less stay-time in the ICU than placebo cohort. 
There was no significant difference in both groups 
in terms of the length of hospital stay [10]. The 
earlier infusion of levosimendan protects the 
myocardium and the other body organs and 
subsequently reduces the rate of complications 
after cardiac surgery in patients with 
compromised cardiac function [11]. Furthermore, 
the perioperative use of levosimendan in high-risk 
patients was associated with significantly less ICU 
stay when compared with the IABP [12].  
We found a reduction in mortality in the 
levosimendan group. We have noticed that most 
mortality cases were those patients who faced the 
difficulty of weaning from CPB. This finding 
supports the benefit of early levosimendan 
utilization. Many authors reported the same 
results with a significant reduction in mortality in 
levosimendan versus control groups [7, 8, 10, 13]. 
Moreover, in studies comparing the 
intraoperative versus the ICU use of the drug, they 
found a significant reduction in early mortality 
[11]. Other authors reported a non-significant 
reduction in deaths in the levosimendan group 
[6]. A recent meta-analysis concluded that 
levosimendan reduced mortality but not to a 
significant level [14]. 
Levosimendan side effects: 
One of the most frequent adverse effects of 
levosimendan is a headache. The incidence of 
headaches in such patients was up to 40% [15]. 
The presence of headaches was not significant 
among our patients. When present, it was relieved 
by simple analgesics. 
The incidence of significant hypotension was 
higher in the levosimendan group (37.3% versus 
30.7%). This problem was obvious when using the 
initial loading dose or after developing low 
cardiac output. It was associated with increased 
demands for high doses of vasoconstrictor agents 
with harmful renal perfusion effects. Eriksson and 
coworkers reported the same results. They 
noticed that vasoconstrictors use was significantly 
higher in the levosimendan group [16]. 
The evidence regarding levosimendan to cause 
arrhythmia is conflicting. There was no significant 
difference between both groups regarding the 
development of AF, VT, or VF. Many authors 
observed similar results [6, 13]. 
 The SURVIVE trial compared levosimendan's 
efficacy and safety versus dobutamine in acute 
myocardial dysfunction in 1327 patients. In the 
levosimendan group, patients were more likely to 
experience atrial fibrillation with a non-significant 
difference in developing ventricular tachycardia 
[16]. Furthermore, A higher incidence of 
ventricular arrhythmias was noticed in the 
levosimendan group versus placebo in the REVIVE 
trial [17]. 
Limitations of the study: 
The detailed preoperative data of coronary 
artery anatomy, previous stenting, and 
preoperative myocardial infarction events were 
not analyzed. The type of cardioplegia was not 
uniform as in many cases we used HTK solution. 
The sharp definition of LCOP and the decision of 
IABP placement or adding additional inotropes 
were not standardized. 
Conclusion 
The preoperative use of levosimendan could 
improve the outcomes in patients undergoing 
coronary artery bypass surgery with low ejection 
fraction. Levosimendan complication profile was 
comparable to the conventional approach. 
Conflict of interest: Authors declare no conflict of 
interest. 
References 
1. Tritapepe L, De Santis V, Vitale D, et al.
Levosimendan pre-treatment improves






artery bypass graft surgery. Br J Anaesth. 2009; 
102: 198–204. 
2. Elahi M, Lam J, Asopa S, et al. Levosimendan
Versus an Intra-aortic Balloon Pump in Adult
Cardiac Surgery Patients With Low Cardiac
Output. Journal of Cardiothoracic and Vascular
Anesthesia. 2011; 25 (6): 1154-1162.
3. Jentzer JC, Coons JC, Link CB, Schmidhofer M.
Pharmacotherapy update on the use of
vasopressors and inotropes in the intensive
care unit. J Cardiovasc Pharmacol Ther. 2015;
20: 249–60.
4. Shi W, Li S, Collins N, et al. Peri-operative
Levosimendan in Patients Undergoing Cardiac
Surgery: An Overview of the Evidence. Heart,
Lung and Circulation. 2015; 24, 667–672.
5. Faisal S, Apatov D, Ramakrishna H, Weiner
MM. Levosimendan in Cardiac Surgery:
Evaluating the Evidence. Journal of
Cardiothoracic and Vascular Anesthesia. 2019;
33: 1146-1158.
6. Mehta R, Leimberger J, van Diepen S.
Levosimendan in patients with left ventricular
dysfunction undergoing cardiac surgery. The
New England Journal of Medicine. 2017; 376
(21): 2032–2042.
7. Levin R, Degrange M, Del Mazo C, Tanus E,
Porcile R. Preoperative levosimendan
decreases mortality and the development of
low cardiac output in high-risk patients with
severe left ventricular dysfunction undergoing
coronary artery bypass grafting with
cardiopulmonary bypass. Experimental &
Clinical Cardiology. 2012; 17 (3): 125–130.
8. Harrison RW, Hasselblad V, Mehta RH, Levin R,
Harrington RA, Alexander JH. Effect of
levosimendan on survival and adverse events
after cardiac surgery: A meta-analysis. J
Cardiothorac Vasc Anesth. 2013; 27: 1224–32.
9. Toller W, Heringlake M, Guarracino F, et al.
Preoperative and perioperative use of
levosimendan in cardiac surgery: European
expert opinion. International Journal of
Cardiology. 2015; 184 (1): 323–336.
10. Ng K, Chan X, Tan W, Wang CY. Levosimendan
use in patients with preoperative low ejection 
fraction undergoing cardiac surgery: A 
systematic review with meta-analysis and trial 
sequential analysis. Journal of Clinical 
Anesthesia. 2019; 52: 37–47. 
11. Tasouli A, Papadoupolos K, Antoniou T, et al.
Efficacy and safety of perioperative infusion of
levosimendan in patient with compromised
cardiac function undergoing open-heart
surgery: Importance of early use. Eur J
Cardiothorac Surg. 2007; 32: 629-33.
12. Severi L, Lappa A, Landoni G. Levosimendan
Versus Intra-aortic Balloon Pump in High-Risk
Cardiac Surgery Patients. Journal of
Cardiothoracic and Vascular Anesthesia. 2011;
25 (4): 632-636.
13. Wang B, He X, Gong Y, Cheng B. Levosimendan
in Patients with Left Ventricular Dysfunction
Undergoing Cardiac Surgery: An Update Meta-
Analysis and Trial Sequential Analysis. Hindawi
BioMed Research International. 2018, Article
ID 7563083.
14. Lee CT, Lin YC, Yeh YC, Chen TL, Chen CY.
Effects of levosimendan for perioperative
cardiovascular dysfunction in patients
receiving cardiac surgery: a meta-analysis with
trial sequential analysis. Intensive Care Med.
2017; 43,1929–1930.
15. Lehtonen L, Mills-Owens P, Akkila J. Safety of
levosimendan and other calcium sensitizers. J
Cardiovasc Pharmacol. 1995; 26(Suppl 1): S70–
6.
16. Eriksson HI, Jalonen JR, Heikkinen LO, et al.
Levosimendan facilitates weaning from
cardiopulmonary bypass in patients
undergoing coronary artery bypass grafting
with impaired left ventricular function. The
Annals of Thoracic Surgery. 2009; 87 (2): 448–
454. 
17. Cleland JG, Freemantle N, Coletta AP, Clark AL.
Clinical trials update from the American Heart
Association: REPAIR-AMI, ASTAMI, JELIS,
MEGA, REVIVE-II, SURVIVE, and PROACTIVE.
Eur J Heart Fail. 2006; 8:105–10.
The Egyptian Cardiothoracic Surgeon 
I  
Pr
ss
